Long-Term Treatment with First-Line Amivantamab Plus Lazertinib: Impact of Treatment Discontinuation, Maintenance, and Early Adverse Event Management on Duration of Therapy

Authors

• Danny Nguyen
• Alexander I. Spira
• Hidetoshi Hayashi
• Scott Owen
• Ernesto Korbenfeld
• Jeronimo R. Rodriguez Cid
• Claudio Martin
• Seema Sethi
• Sujay Shah
• Andy L. Johnson
• Elizabeth Fennema
• Yichuan Xia
• Shirish M. Gadgeel, Henry Ford HealthFollow

Recommended Citation

Nguyen D, Spira AI, Hayashi H, Owen S, Korbenfeld E, Rodriguez Cid JR, Martin C, Sethi S, Shah S, Johnson AL, Fennema E, Xia Y, Gadgeel SM. Long-Term Treatment with First-Line Amivantamab Plus Lazertinib: Impact of Treatment Discontinuation, Maintenance, and Early Adverse Event Management on Duration of Therapy. J Thorac Oncol 2026; 21(5):2.

Document Type

Conference Proceeding

Publication Date

5-1-2026

Publication Title

J Thorac Oncol

Keywords

Oncology, Respiratory System

Abstract

In MARIPOSA, first-line amivantamab-lazertinib significantly improved overall survival (OS) versus osimertinib, with a projected median OS of >4 years (Yang NEJM 2025). Since approval, the amivantamab-lazertinib safety profile has been further optimized using prophylactic regimens as demonstrated in the SKIPPirr (IRR reduction 2-fold) and COCOON (dermatologic adverse event [AE] reduction ∼2-fold) trials. In MARIPOSA, first onset of key AEs mostly occurred during the first 4 months (Spira NACLC 2023). Nearly half (49%) of dose interruptions occurred in the first 4 months, and these did not impact PFS (Campelo ELCC 2024). Here, we present an analysis of long-term treatment duration of amivantamab-lazertinib and osimertinib, including assessing characteristics of participants who remained on therapy for ≥ 3 years.

Volume

21

Issue

5

First Page

2